Furthermore, IHC staining demonstrated that treatment with ponatinib resulted in a loss of Myc and Olig2 expression accompanied by increased level of p65-NFkB, a marker associated with tumor core (hypovascular) cells30 (Fig. S7e). Here, OLIG2 is linked to neoplasm.